RIGImmune Inc.
PrivateLast Round
Series A
Apr 1, 2024
Est. Valuation
$18.25M
Total Funding Raised
$15M
Company Overview
RIGImmune Inc. is a biopharmaceutical company developing a new class of RNA immunotherapeutics that selectively activate the innate immune sensor RIG-I to treat diseases caused by RNA viruses and to induce antitumor immune responses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RIGImmune Inc. Comparables
Compare RIGImmune Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merck & Co., Inc. | 77% | |
| Xanadu Bio | 77% | |
| NorthLinks Bio | 76% |
RIGImmune Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 1, 2024 | ||||
| Grant | Dec 7, 2022 | ||||
| VC Round | Dec 7, 2022 | ||||
| VC Round | Sep 15, 2022 | ||||
| Seed | Dec 10, 2021 |
Key People
Founding team and executive leadership
RIGImmune Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rivermount Ventures | VC Round |
| Bill & Melinda Gates Foundation | VC Round, Grant |
| Yale Ventures | Seed |
| F-Prime Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
Monthly visitors increased 219% MoM.
- Apr 1, 2024
Completed a Series A funding round.
RIGImmune Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about RIGImmune Inc.'s valuation, stock price, and market status.
Is RIGImmune Inc. a public or private company?
RIGImmune Inc. is a private company.
What is the current stock price of RIGImmune Inc.?
RIGImmune Inc. is a private company, so its shares have no public market price. Caplight tracks RIGImmune Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RIGImmune Inc. worth (valuation)?
RIGImmune Inc.'s valuation is estimated at $18.3M based on funding round data.
Can I buy RIGImmune Inc. stock?
RIGImmune Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RIGImmune Inc.'s last funding round?
RIGImmune Inc.'s most recent funding round was Series A on April 1, 2024.
Who are the main investors in RIGImmune Inc.?
Key investors in RIGImmune Inc. include F-Prime Capital.
Will RIGImmune Inc. IPO soon?
No public IPO plans have been announced for RIGImmune Inc..
How can I track RIGImmune Inc. secondary market activity?
Caplight tracks bids, offers, and trades in RIGImmune Inc.'s shares on secondary markets.